Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Withdrawn2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_3

Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA

NCT02739568
withdrawnphase_3

Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

NCT02978651
withdrawnphase_2

A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment

NCT02800083

Clinical Trials (3)

Showing 3 of 3 trials
NCT02739568Phase 3

Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA

Completed
NCT02978651Phase 3

Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

Withdrawn
NCT02800083Phase 2

A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3